Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? (2014)

First Author: Cosman F
Attributed to:  CIMA: The Centre for Integrated Research into Musculoskeletal Ageing funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1210/jc.2014-1971

PubMed Identifier: 25215556

Publication URI: http://europepmc.org/abstract/MED/25215556

Type: Journal Article/Review

Volume: 99

Parent Publication: The Journal of clinical endocrinology and metabolism

Issue: 12

ISSN: 0021-972X